Company: OXBRW
Filing Date: 2025-02-26
Form Type: 424B5
Source: 0001493152-25-008248
Chunk: 24

Company: OXBRIDGE RE HOLDINGS Ltd
Filing Date: 2025-02-26
Form: 424B5
Chunk 24
---
 other material relating to us or our ordinary shares in any jurisdiction where action for that purpose is required. Accordingly, our ordinary shares may not be offered or sold, directly or indirectly, and none of this prospectus supplement, the accompanying prospectus or any other offering material or advertisements in connection with our ordinary shares may be distributed or published, in or from any country or jurisdiction, except in compliance with any applicable rules and regulations of any such country or jurisdiction.

The placement agent may arrange to sell the ordinary shares offered hereby in certain jurisdictions outside the United States, either directly or through affiliates, where they are permitted to do so.

Affiliations

The placement agent and its affiliates have provided, and may in the future provide, various investment banking, financial advisory and other financial services to us and our affiliates for which they have received, and in the future may receive, advisory or transaction fees, as applicable. The placement agent is party to an equity distribution agreement with us dated September 30, 2022, relating to the sale of the ordinary shares from time to time through the placement agent, acting as our sales agent. Except as disclosed in this prospectus supplement, we have no present arrangements with the placement agent for any further services.

| S-13 |

<div align='center'>PRIVATE PLACEMENT TRANSACTION</div>

Concurrently with the sale of shares of ordinary shares in this offering, we will issue and sell to certain investors two accompanying ordinary share warrants to purchase an aggregate of up to 1,411,768 ordinary shares, which ordinary share warrants have an exercise price of $4.25 per ordinary share. The Series A ordinary share warrants will be immediately exercisable, will expire two years from the initial exercise date and will have an exercise price of $4.25 per share. The Series B ordinary share warrants will be exercisable on the earlier of the date of shareholder approval or 6 months from the date issuance, will expire five years from the initial exercise date and will have an exercise price equal to the lower of (i) $5.00 and (ii) from and after the date we receive shareholder approval, $4.25 per share. We have agreed to hold an annual or special meeting on or before June 30, 2025 to have shareholders approve the issuance of the ordinary shares underlying the Series B Warrants pursuant to applicable Nasdaq rules.

The ordinary share warrants and the ordinary shares issuable upon the exercise of the ordinary share warrants are not being registered under the Securities Act of 1933, as amended